Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Human Recombinant Fibroblast Growth Factor-1 (FGF-1), for the Treatment of Subjects With Severe Coronary Heart Disease, a Placebo Controlled, Double-blind, Dose-varying Study

NCT00117936 is registered in ClinicalTrials.gov with Venturis Therapeutics, Inc. as lead sponsor.

NCT NCT00117936
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00117936 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Human Recombinant Fibroblast Growth Factor-1 (FGF-1), for the Treatment of Subjects With Severe Coronary Heart Disease, a Placebo Controlled, Double-blind, Dose-varying Study
Lead sponsor
Venturis Therapeutics, Inc.
Phase
Phase 2
Overall status
Not yet recruiting
Start date
September 1, 2027
Completion date
June 15, 2030
Enrollment
150 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

coronary arteriosclerosis, coronary disease, coronary heart disease, myocardial ischemia